<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837808</url>
  </required_header>
  <id_info>
    <org_study_id>2018-FXY-206</org_study_id>
    <nct_id>NCT03837808</nct_id>
  </id_info>
  <brief_title>Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Randomized Phase III Non-inferiority Study of Radiotherapy Plus Concurrent Nimotuzumab Versus Cisplatin in Stage II-III Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined
      with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III
      nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scheme:

      Eligible stage II and III NPC patients will first be stratified by institution, then
      randomized to 2 arms at 1:1 ratio.

      - Arm Cisplatin: cisplatin 40mg/m2/week in concurrent with IMRT

      - Arm nimotuzumab: nimotuzumab 200mg/week in concurrent with IMRT
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">February 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Progress-free survival is calculated from the date of randomization to the date of the first progress at any site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival (LRRFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">384</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Nasopharyngeal Neoplasms</condition>
  <condition>Nasopharyngeal Diseases</condition>
  <condition>Head and Neck Neoplasm</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nimotuzumab 200mg/week in concurrent with IMRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cisplatin 40mg/m2/week in concurrent with IMRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimotuzumab</intervention_name>
    <description>nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT</description>
    <arm_group_label>Nimotuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT</description>
    <arm_group_label>Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing nasopharyngeal
             carcinoma, including WHO II or III

          -  histologically confirmed positive EGFR expression

          -  Stage II and III NPC patients（according to the 8th AJCC edition）

          -  Male and no pregnant female

          -  Age between 18-65

          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count
             ≥100000/μL

          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;2.0×upper limit of normal (ULN)

          -  Adequate renal function: creatinine clearance ≥60 ml/min

          -  Satisfactory performance status: Karnofsky scale (KPS) &gt; 70

          -  Without radiotherapy or chemotherapy

          -  Patients must give signed informed consent

        Exclusion Criteria:

          -  Evidence of relapse or distant metastasis

          -  History of prior malignancy or previous treatment for NPC

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <phone>+86-20-87343361</phone>
    <email>chenmy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui-Hua Xu, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

